Solventum Corporation (SOLV) Stock Forecast & Price Target

Compare

291 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SOLV Analyst Ratings

Moderate Buy

7 Buy

3 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Solventum

Corporation

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SOLV Stock 12 Month Forecast

Average Price Target

$95.33

▲(38.97% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Solventum Corporation in the last 3 months. The average price target is $95.33 with a high forecast of $105.00 and a low forecast of $82.00. The average price target represents a 38.97% change from the last price of $68.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"$64","85":"$85","106":"$106","74.5":"$74.5","95.5":"$95.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$95.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$82.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,74.5,85,95.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,75.46153846153847,77.92307692307692,80.38461538461539,82.84615384615384,85.3076923076923,87.76923076923077,90.23076923076923,92.6923076923077,95.15384615384616,97.61538461538461,100.07692307692308,102.53846153846155,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,74.7176923076923,76.43538461538462,78.15307692307692,79.87076923076923,81.58846153846153,83.30615384615385,85.02384615384615,86.74153846153845,88.45923076923077,90.17692307692307,91.89461538461538,93.6123076923077,{"y":95.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,73,73.6923076923077,74.38461538461539,75.07692307692308,75.76923076923077,76.46153846153847,77.15384615384616,77.84615384615384,78.53846153846153,79.23076923076923,79.92307692307692,80.61538461538461,81.3076923076923,{"y":82,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":79.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 56, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 73, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 63, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.56,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.91,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$105.00

Average Price Target$95.33

Lowest Price Target$82.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Wood

Morgan Stanley

$103

Buy

50.15%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Veeva Systems (NYSE: VEEV), BillionToOne, Inc. Class A (NASDAQ: BLLN) and Solventum Corporation (NYSE: SOLV)

Kevin Caliendo

UBS

$79→$82

Hold

19.53%

Upside

Reiterated

03/02/26

UBS Reaffirms Their Hold Rating on Solventum Corporation (SOLV)

Rick Wise

Stifel Nicolaus

$105

Buy

53.06%

Upside

Reiterated

02/27/26

Solventum Corporation (SOLV) Receives a Buy from Stifel Nicolaus

Brett Fishbin

KeyBanc

$97→$99

Buy

44.31%

Upside

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)

Jason Bednar

Piper Sandler

$98

Buy

42.86%

Upside

Reiterated

02/27/26

Solventum Corporation (SOLV) Receives a Buy from Piper Sandler

Ryan Zimmerman

BTIG

$100

Buy

45.77%

Upside

Reiterated

02/26/26

BTIG Reaffirms Their Buy Rating on Solventum Corporation (SOLV)

Travis Steed

Bank of America Securities

$85

Hold

23.91%

Upside

Reiterated

02/15/26

Balanced View on Solventum: Differentiated Healthcare IT AI Offsets Early-Stage Turnaround Risk, Supporting a Hold Rating

Steven Valiquette

Mizuho Securities

$85→$100

Buy

45.77%

Upside

Upgraded

01/20/26

Mizuho Securities upgrades Solventum Corporation (SOLV) to a Buy

Vik Chopra

Wells Fargo

$86

Hold

25.36%

Upside

Reiterated

01/13/26

Solventum Corporation (SOLV) Receives a Hold from Wells Fargo

David Toung

Argus Research

―

Buy

―

Reiterated

12/12/25

Argus Research Remains a Buy on Solventum Corporation (SOLV)

Michael Toomey

Jefferies

$80

Hold

16.62%

Upside

Initiated

09/10/25

Hold Rating on Solventum Corporation: Steady Growth and Valuation Challenges Post-Spin-Off

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Wood

Morgan Stanley

$103

Buy

50.15%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Veeva Systems (NYSE: VEEV), BillionToOne, Inc. Class A (NASDAQ: BLLN) and Solventum Corporation (NYSE: SOLV)

Kevin Caliendo

UBS

$79→$82

Hold

19.53%

Upside

Reiterated

03/02/26

UBS Reaffirms Their Hold Rating on Solventum Corporation (SOLV)

Rick Wise

Stifel Nicolaus

$105

Buy

53.06%

Upside

Reiterated

02/27/26

Solventum Corporation (SOLV) Receives a Buy from Stifel Nicolaus

Brett Fishbin

KeyBanc

$97→$99

Buy

44.31%

Upside

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)

Jason Bednar

Piper Sandler

$98

Buy

42.86%

Upside

Reiterated

02/27/26

Solventum Corporation (SOLV) Receives a Buy from Piper Sandler

Ryan Zimmerman

BTIG

$100

Buy

45.77%

Upside

Reiterated

02/26/26

BTIG Reaffirms Their Buy Rating on Solventum Corporation (SOLV)

Travis Steed

Bank of America Securities

$85

Hold

23.91%

Upside

Reiterated

02/15/26

Balanced View on Solventum: Differentiated Healthcare IT AI Offsets Early-Stage Turnaround Risk, Supporting a Hold Rating

Steven Valiquette

Mizuho Securities

$85→$100

Buy

45.77%

Upside

Upgraded

01/20/26

Mizuho Securities upgrades Solventum Corporation (SOLV) to a Buy

Vik Chopra

Wells Fargo

$86

Hold

25.36%

Upside

Reiterated

01/13/26

Solventum Corporation (SOLV) Receives a Hold from Wells Fargo

David Toung

Argus Research

―

Buy

―

Reiterated

12/12/25

Argus Research Remains a Buy on Solventum Corporation (SOLV)

Michael Toomey

Jefferies

$80

Hold

16.62%

Upside

Initiated

09/10/25

Hold Rating on Solventum Corporation: Steady Growth and Valuation Challenges Post-Spin-Off

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Solventum Corporation

3 Months

xxx

Success Rate

5/10 ratings generated profit

Average Return

-0.81%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.81% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

2/10 ratings generated profit

Average Return

-4.12%

reiterated a buy rating 12 days ago

Copying Rick Wise's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -4.12% per trade.

2 Years

xxx

Success Rate

1/10 ratings generated profit

Average Return

-6.87%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 10.00% of your transactions generating a profit, with an average return of -6.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SOLV Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SOLV has received 13 Buy Ratings, 37 Hold Ratings, and 0 Sell Ratings. SOLV average Analyst price target in the past 3 months is 95.33.

Each month's total comprises the sum of three months' worth of ratings.

SOLV Financial Forecast

SOLV Earnings Forecast

Next quarter’s earnings estimate for SOLV is $1.35 with a range of $1.32 to $1.38. The previous quarter’s EPS was $1.57. SOLV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SOLV has Performed in-line its overall industry.

SOLV Sales Forecast

Next quarter’s sales forecast for SOLV is $1.97B with a range of $1.94B to $2.00B. The previous quarter’s sales results were $2.00B. SOLV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SOLV has Performed in-line its overall industry.

SOLV Stock Forecast FAQ

What is SOLV’s average 12-month price target, according to analysts?

Based on analyst ratings, Solventum Corporation’s 12-month average price target is 95.33.

What is SOLV’s upside potential, based on the analysts’ average price target?

Solventum Corporation has 38.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SOLV a Buy, Sell or Hold?

Solventum Corporation has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.

What is Solventum Corporation’s price target?

The average price target for Solventum Corporation is 95.33. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $105.00 ,the lowest forecast is $82.00. The average price target represents 38.97% Increase from the current price of $68.6.

What do analysts say about Solventum Corporation?

Solventum Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of SOLV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Solventum Corporation (SOLV) Stock Forecast & Price Target

SOLV Analyst Ratings

SOLV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Solventum Corporation

SOLV Analyst Recommendation Trends

SOLV Financial Forecast

SOLV Earnings Forecast

SOLV Sales Forecast

SOLV Stock Forecast FAQ

Detailed List of Analyst Forecasts